|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.150 AUD | -4.17% |
|
-12.21% | -52.08% |
| Nov. 02 | OncoSil Medical Limited Announces Retirement of Doug Cubbin as Independent Non-Executive Director | CI |
| Oct. 15 | OncoSil Medical Reports First Pancreatic Cancer Device Treatment in Germany | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Life Sciences Tools and Services | ||||||||||
Device development for new medical treatments | 1.3M | 1.06M | 1.47M | 1.57M | 1.54M | |||||
Total Assets | 14.15M | 13.07M | 11.47M | 6.72M | 7.15M | |||||
Interest Expense | -15.75K | -19.62K | -10.9K | -3.94K | -877 | |||||
CAPEX | -54K | -5.83K | -57.82K | -197K | -14.96K | |||||
EBT | -10.43M | -10.73M | -11.34M | -11.91M | -15.1M | |||||
D&A | 185K | 192K | 176K | 44K | 35.74K | |||||
Net Income | -10.43M | -10.73M | -11.34M | -11.91M | -15.1M |
Geographical Revenue Distribution History
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Europe | - | - | 112K | 457K | 870K | |||||
Middle East | - | - | - | - | 286K | |||||
Australia | - | - | - | - | 15K | |||||
APAC (Australia and New Zealand) | 213K | 232K | 256K | 60K | - |
- Stock Market
- Equities
- OSL Stock
- Financials OncoSil Medical Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
